InSite Vision Announces Clinical Development Plan for ISV-502

ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV) today reported that the company recently met with the U.S. Food and Drug Administration (FDA or “the Agency”) regarding the Phase 3 clinical program for ISV-502 (AzaSite Plus™). ISV-502 is a topical combination antibiotic/corticosteroid product formulated with InSite Vision’s patented DuraSite® technology to enhance the retention time of the therapeutic agents on the surface of the eye leading to increased ocular tissue concentrations.
MORE ON THIS TOPIC